IVERIC bio, Inc. (ISEE): Price and Financial Metrics

IVERIC bio, Inc. (ISEE)

Today's Latest Price: $6.62 USD

0.32 (5.08%)

Updated Nov 27 1:00pm

Add ISEE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

ISEE Stock Price Chart Interactive Chart >

Price chart for ISEE

ISEE Price/Volume Stats

Current price $6.62 52-week high $8.97
Prev. close $6.30 52-week low $2.64
Day low $6.30 Volume 336,300
Day high $6.70 Avg. volume 779,082
50-day MA $5.99 Dividend yield N/A
200-day MA $4.83 Market Cap 592.94M

IVERIC bio, Inc. (ISEE) Company Bio

IVERIC bio, Inc. (formerly Ophthotech Corporation) is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). The company was founded in 2007 and is based in New York, New York.

ISEE Latest News Stream

Event/Time News Detail
Loading, please wait...

ISEE Latest Social Stream

Loading social stream, please wait...

View Full ISEE Social Stream

Latest ISEE News From Around the Web

Below are the latest news stories about IVERIC bio Inc that investors may wish to consider to help them evaluate ISEE as an investment opportunity.

What You Need To Know About IVERIC bio, Inc.'s (NASDAQ:ISEE) Investor Composition

If you want to know who really controls IVERIC bio, Inc. (NASDAQ:ISEE), then you'll have to look at the makeup of its...

Yahoo | July 27, 2020

Did Hedge Funds Make The Right Call On IVERIC bio, Inc. (ISEE) ?

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | July 17, 2020

IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors

IVERIC bio announced the election of Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors, effective as of July 15, 2020.

Yahoo | July 16, 2020

Moving Average Crossover Alert: IVERIC bio

IVERIC bio, Inc. (ISEE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Yahoo | July 3, 2020

Iveric bio launches second pivotal study of Zimura in eye disorder

The first patient has been dosed in a second pivotal clinical trial, Phase 3 GATHER2, evaluating IVERIC bio's (ISEE) Zimura (avacincaptad pegol), a complement C5 inhibitor, in patients with geographic atrophy ((GA)) secondary to age-related macular degeneration.The primary endpoint of the 400-subject study is the mean rate of change in GA...

Seeking Alpha | June 30, 2020

Read More 'ISEE' Stories Here

ISEE Price Returns

1-mo 11.82%
3-mo 47.44%
6-mo 58.00%
1-year 95.86%
3-year 110.83%
5-year -89.59%
YTD -22.84%
2019 615.00%
2018 -61.54%
2017 -35.40%
2016 -93.85%
2015 75.02%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.862 seconds.